| Luis Alonso Hernandez Mejia, MD | |
|
353 Fairmont Blvd, Rapid City, SD 57701-7375 | |
| (605) 755-1000 | |
| Not Available |
| Full Name | Luis Alonso Hernandez Mejia |
|---|---|
| Gender | Male |
| Speciality | Advanced Heart Failure And Transplant Cardiology |
| Experience | 12 Years |
| Location | 353 Fairmont Blvd, Rapid City, South Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750766317 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 11872 (South Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Monument Health Rapid City Hospital | Rapid city, SD | Hospital |
| Monument Health Spearfish Hospital | Spearfish, SD | Hospital |
| Monument Health Sturgis Hospital | Sturgis, SD | Hospital |
| Monument Health Custer Hospital | Custer, SD | Hospital |
| Chadron Community Hospital And Health Services | Chadron, NE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Monument Health Rapid City Hospital, Inc. | 6002729506 | 424 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
Standard neurological exams of older adults are good predictors of future brain health and quality of life. These tests should become part of the physician's routine examination of older adults say faculty from the Indiana University Center for Aging Research in an editorial in the June 23, 2008 issue of the Archives of Internal Medicine.
Non-communicable, chronic lung diseases are a major burden on health worldwide. About 80 million people suffer from COPD globally and a further 300 million are affected by asthma.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, and Ex Libris Group, a global leader in the provision of library automation solutions, today announced their collaboration to make the full text of SciVerse ScienceDirect journal articles and ebooks searchable in the Ex Libris Primo Central Index.
› Verified 2 days ago
| Entity Name | Monument Health Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588185268 PECOS PAC ID: 5991616427 Enrollment ID: O20031111000854 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
Standard neurological exams of older adults are good predictors of future brain health and quality of life. These tests should become part of the physician's routine examination of older adults say faculty from the Indiana University Center for Aging Research in an editorial in the June 23, 2008 issue of the Archives of Internal Medicine.
Non-communicable, chronic lung diseases are a major burden on health worldwide. About 80 million people suffer from COPD globally and a further 300 million are affected by asthma.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, and Ex Libris Group, a global leader in the provision of library automation solutions, today announced their collaboration to make the full text of SciVerse ScienceDirect journal articles and ebooks searchable in the Ex Libris Primo Central Index.
› Verified 2 days ago
| Entity Name | Monument Health Rapid City Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275553463 PECOS PAC ID: 6002729506 Enrollment ID: O20070625000144 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
Standard neurological exams of older adults are good predictors of future brain health and quality of life. These tests should become part of the physician's routine examination of older adults say faculty from the Indiana University Center for Aging Research in an editorial in the June 23, 2008 issue of the Archives of Internal Medicine.
Non-communicable, chronic lung diseases are a major burden on health worldwide. About 80 million people suffer from COPD globally and a further 300 million are affected by asthma.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, and Ex Libris Group, a global leader in the provision of library automation solutions, today announced their collaboration to make the full text of SciVerse ScienceDirect journal articles and ebooks searchable in the Ex Libris Primo Central Index.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Luis Alonso Hernandez Mejia, MD 353 Fairmont Blvd, Rapid City, SD 57701-7375 Ph: (605) 755-1000 | Luis Alonso Hernandez Mejia, MD 353 Fairmont Blvd, Rapid City, SD 57701-7375 Ph: (605) 755-1000 |
News Archive
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
Standard neurological exams of older adults are good predictors of future brain health and quality of life. These tests should become part of the physician's routine examination of older adults say faculty from the Indiana University Center for Aging Research in an editorial in the June 23, 2008 issue of the Archives of Internal Medicine.
Non-communicable, chronic lung diseases are a major burden on health worldwide. About 80 million people suffer from COPD globally and a further 300 million are affected by asthma.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, and Ex Libris Group, a global leader in the provision of library automation solutions, today announced their collaboration to make the full text of SciVerse ScienceDirect journal articles and ebooks searchable in the Ex Libris Primo Central Index.
› Verified 2 days ago
Cliff Janikowski, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 353 Fairmont Blvd, Rapid City, SD 57701 Phone: 605-755-1000 | |
Dr. James A Engelbrecht, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 640 Flormann St, Rapid City, SD 57701 Phone: 605-718-3300 Fax: 605-718-3426 | |
James Michael Keegan, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4940 5th St, Suite 1b, Rapid City, SD 57701 Phone: 605-342-8329 | |
Santosh Raj Poudel, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 353 Fairmont Blvd., Rapid City, SD 57701 Phone: 605-719-1000 Fax: 605-719-8826 | |
Dr. Oksana Anand, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2820 Mount Rushmore Rd, Rapid City, SD 57701 Phone: 605-342-3280 | |
Masaru Chiba, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2805 5th St, Suite 100, Rapid City, SD 57701 Phone: 605-719-5700 Fax: 605-719-5701 | |
John Palmer, DO Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 640 Flormann St, Rapid City, SD 57701 Phone: 605-755-3300 Fax: 605-755-3129 |